All updated as on -
The Glaucoma Treatment Market size is estimated to be USD 8.19 billion in 2023 and USD 12.14 billion in 2030, growing at a CAGR of 6.13% from 2023 to 2030.
Two key drivers of market development are rising occurrence rates and increased desire for novel therapeutic choices. The World Glaucoma Association estimates that by 2020, 79.6 million people worldwide will have glaucoma. In 2040, there will probably be 111.8 million people on the earth. The market is comprehensively evaluated in the study on the global glaucoma treatment market. The research provides a thorough analysis of the market's key segments, trends, drivers, restraints, competitive environment, and other important variables.
The introduction of fixed-dose combination medicines, which include medications from different classes, is anticipated to considerably increase demand for glaucoma therapy. With the launch of first-in-class, cutting-edge medications like trabodenoson, vesneo, and roclatan/rhopressa, the market for treating glaucoma will enter a new phase of growth. The prevalence of glaucoma is rising along with the global geriatric population growth because older people are more likely to get glaucoma. Additionally, a growing number of diabetics and individuals with a family history of glaucoma greatly increase the prevalence of this condition. Governments and healthcare organizations are working harder than ever to raise public knowledge of the various glaucoma treatment choices.
A group of eye conditions known as glaucoma harm the optic nerve, which carries visual information from the eye to the brain. If left untreated, this damage may result in vision loss and eventually blindness. In most cases, glaucoma treatment involves reducing intraocular pressure (IOP) in the affected eye or eyes. Glaucoma can be treated using a variety of methods, such as medication, laser therapy, and surgery. Globally, glaucoma is the second-leading cause of blindness. During routine eye checkups, a tonometer is used to measure intraocular pressure (IOP). IOP should usually be lower than 21 mmHg. Treatment for glaucoma may involve surgery, laser therapy, or medication, depending on its severity. The main goal of most eye drops is to lower IOP, which is the first line of defense against glaucoma.
Most people become careless when it comes to carefully utilizing eye drops, and neglecting to take prescribed medications is a major contributor to blindness. The initial line of glaucoma therapy is typically medication. Eye drops are the most common kind of treatment used to decrease IOP. These drops work by altering the amount of fluid produced in the eye. Beta-blockers, prostaglandin analogs, alpha-adrenergic agonists, and carbonic anhydrase inhibitors are just a few of the several categories of eye drops. Each class of medicine functions differently and could have a range of negative effects.
The global glaucoma treatment industry is primarily being driven by an increase in glaucoma patients. Glaucoma is a painless eye condition that doesn't create symptoms until significant vision loss, therefore the number of people who have it is increasing daily. The glaucoma treatment industry is also growing as a result of government and pharmaceutical company initiatives to raise awareness of the disease. Since eye drops are the primary glaucoma control method, technological advancements in therapy are another factor fueling growth in the glaucoma therapy sector. In addition, several pharmaceutical and biotech companies are investing in innovative glaucoma treatments.
Alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs are some of the drugs used to treat glaucoma. Combinations of drugs are also frequently employed. As a result of the current development of several pipeline medicines for the illness, the market will rise during the projection period. In April 2022, Skye Bioscience will begin a Phase I trial for SBI-100 Ophthalmic Emulsion in collaboration with CMAX Clinical Research. Skye will receive assistance from CMAX, one of the most well-known early-phase trial personnel in the world, with subject recruitment and study drug administration to healthy volunteers. Thus, product launches and clinical trial products fuel the growth of the glaucoma market during the course of the forecasted time.
The market for glaucoma therapy may expand using alternative methods that don't involve much medication and provide long-lasting relief. The laser procedure known as selective laser trabeculoplasty and minimally invasive glaucoma procedures, or MIGs, are two alternate methods for treating glaucoma. Both of these methods work to lower intraocular pressure by encouraging a greater flow of fluid from the patient's eye. However, there has been a decline in the number of patients choosing SLTs and MIGs as a result of the global pandemic brought on by the new coronavirus epidemic. As glaucoma has been classified as "elective" in many nations, patients prefer to use prescription eye drops and drugs to delay the disease's progression. Many patients are currently delaying their elective glaucoma procedures and, as a result, are searching for better, more effective drug options to treat their glaucoma. In the near future, it is projected that this tendency will increase demand for glaucoma treatments.
Report Coverage
Global Glaucoma Treatment research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Glaucoma Treatment report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Glaucoma Treatment competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Glaucoma Treatment market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Glaucoma Treatment market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Glaucoma Treatment market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Merck & Co., Inc., Novartis AG, Allergan Plc, AERIE PHARMACEUTICALS, INC., Bausch & Lomb Incorporated, Akorn Inc, Pfizer Inc, Inotek Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., Aristo Pharmaceuticals Pvt. Ltd., Cipla Incorporation, Fera Pharmaceuticals, AbbVie, Inoteck Pharmaceuticals, among others.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Glaucoma Treatment market based on the below-mentioned segments:
Global Glaucoma Treatment Market, By Drug Class
Beta Blockers
Prostaglandin Analogs
Carbonic Anhydrase Inhibitors
Alpha Agonist
Others
Global Glaucoma Treatment market, By Disease Indication
Open Angle Glaucoma
Closed Angle Glaucoma
Others
Global Glaucoma Treatment market, Regional Analysis
Two key drivers of market development are rising occurrence rates and increased desire for novel therapeutic choices. The World Glaucoma Association estimates that by 2020, 79.6 million people worldwide will have glaucoma. In 2040, there will probably be 111.8 million people on the earth. The market is comprehensively evaluated in the study on the global glaucoma treatment market. The research provides a thorough analysis of the market's key segments, trends, drivers, restraints, competitive environment, and other important variables.
The introduction of fixed-dose combination medicines, which include medications from different classes, is anticipated to considerably increase demand for glaucoma therapy. With the launch of first-in-class, cutting-edge medications like trabodenoson, vesneo, and roclatan/rhopressa, the market for treating glaucoma will enter a new phase of growth. The prevalence of glaucoma is rising along with the global geriatric population growth because older people are more likely to get glaucoma. Additionally, a growing number of diabetics and individuals with a family history of glaucoma greatly increase the prevalence of this condition. Governments and healthcare organizations are working harder than ever to raise public knowledge of the various glaucoma treatment choices.
A group of eye conditions known as glaucoma harm the optic nerve, which carries visual information from the eye to the brain. If left untreated, this damage may result in vision loss and eventually blindness. In most cases, glaucoma treatment involves reducing intraocular pressure (IOP) in the affected eye or eyes. Glaucoma can be treated using a variety of methods, such as medication, laser therapy, and surgery. Globally, glaucoma is the second-leading cause of blindness. During routine eye checkups, a tonometer is used to measure intraocular pressure (IOP). IOP should usually be lower than 21 mmHg. Treatment for glaucoma may involve surgery, laser therapy, or medication, depending on its severity. The main goal of most eye drops is to lower IOP, which is the first line of defense against glaucoma.
Most people become careless when it comes to carefully utilizing eye drops, and neglecting to take prescribed medications is a major contributor to blindness. The initial line of glaucoma therapy is typically medication. Eye drops are the most common kind of treatment used to decrease IOP. These drops work by altering the amount of fluid produced in the eye. Beta-blockers, prostaglandin analogs, alpha-adrenergic agonists, and carbonic anhydrase inhibitors are just a few of the several categories of eye drops. Each class of medicine functions differently and could have a range of negative effects.
The global glaucoma treatment industry is primarily being driven by an increase in glaucoma patients. Glaucoma is a painless eye condition that doesn't create symptoms until significant vision loss, therefore the number of people who have it is increasing daily. The glaucoma treatment industry is also growing as a result of government and pharmaceutical company initiatives to raise awareness of the disease. Since eye drops are the primary glaucoma control method, technological advancements in therapy are another factor fueling growth in the glaucoma therapy sector. In addition, several pharmaceutical and biotech companies are investing in innovative glaucoma treatments.
Alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs are some of the drugs used to treat glaucoma. Combinations of drugs are also frequently employed. As a result of the current development of several pipeline medicines for the illness, the market will rise during the projection period. In April 2022, Skye Bioscience will begin a Phase I trial for SBI-100 Ophthalmic Emulsion in collaboration with CMAX Clinical Research. Skye will receive assistance from CMAX, one of the most well-known early-phase trial personnel in the world, with subject recruitment and study drug administration to healthy volunteers. Thus, product launches and clinical trial products fuel the growth of the glaucoma market during the course of the forecasted time.
The market for glaucoma therapy may expand using alternative methods that don't involve much medication and provide long-lasting relief. The laser procedure known as selective laser trabeculoplasty and minimally invasive glaucoma procedures, or MIGs, are two alternate methods for treating glaucoma. Both of these methods work to lower intraocular pressure by encouraging a greater flow of fluid from the patient's eye. However, there has been a decline in the number of patients choosing SLTs and MIGs as a result of the global pandemic brought on by the new coronavirus epidemic. As glaucoma has been classified as "elective" in many nations, patients prefer to use prescription eye drops and drugs to delay the disease's progression. Many patients are currently delaying their elective glaucoma procedures and, as a result, are searching for better, more effective drug options to treat their glaucoma. In the near future, it is projected that this tendency will increase demand for glaucoma treatments.
Report Coverage
Global Glaucoma Treatment research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Glaucoma Treatment report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Glaucoma Treatment competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Glaucoma Treatment market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Merck & Co., Inc., Novartis AG, Allergan Plc, AERIE PHARMACEUTICALS, INC., Bausch & Lomb Incorporated, Akorn Inc, Pfizer Inc, Inotek Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., Aristo Pharmaceuticals Pvt. Ltd., Cipla Incorporation, Fera Pharmaceuticals, AbbVie, Inoteck Pharmaceuticals, among others. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Glaucoma Treatment Market from 2021 to 2030.
- Market Forecast for Glaucoma Treatment Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Glaucoma Treatment competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Glaucoma Treatment
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Glaucoma Treatment market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Glaucoma Treatment market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Merck & Co., Inc., Novartis AG, Allergan Plc, AERIE PHARMACEUTICALS, INC., Bausch & Lomb Incorporated, Akorn Inc, Pfizer Inc, Inotek Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., Aristo Pharmaceuticals Pvt. Ltd., Cipla Incorporation, Fera Pharmaceuticals, AbbVie, Inoteck Pharmaceuticals, among others.
Primary Target Market
- Market Players of Glaucoma Treatment
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Glaucoma Treatment market based on the below-mentioned segments:
Global Glaucoma Treatment Market, By Drug Class
Beta Blockers
Prostaglandin Analogs
Carbonic Anhydrase Inhibitors
Alpha Agonist
Others
Global Glaucoma Treatment market, By Disease Indication
Open Angle Glaucoma
Closed Angle Glaucoma
Others
Global Glaucoma Treatment market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive glaucoma treatment market market research and competitor analysis for your business to help you develop more profound insights into the glaucoma treatment market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the glaucoma treatment market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.